中国药房2009，Vol.20Issue(32)：2483-2485,3.
莫西沙星与头孢哌酮/舒巴坦钠治疗社区获得性肺炎的最小成本分析
Cost-Minimization Analysis of Cefoperazone/Sulbactam Sodium vs. Moxifloxacin in the Treatment of Community Acquired Pneumonia
许建国 1朱华 1姜正华1
作者信息
- 1. 江苏省苏北人民医院,扬州市,225001
- 折叠
摘要
Abstract
To evaluate the economic effects of cefoperazone/ sulbactam sodium and moxifloxacin for community acquired pneumonia.METHODS: 92 patients with community acquired pneumonia were randomly assigned to receive cefoperazone/ sulbactam sodium for injection(Group A) or moxifloxacin injection(Group B), respectively. In both groups the observation of curative effects and safety and the pharmacoeconomic analysis were conducted. RESULTS: The effective rates of two groups were 86.00% and 92.86% (P>0.05), respectively. The average cost was 1 314.8 yuan in Group A versus 3 306.5 yuan in Group B(P < 0.05). CONCLUSION: The therapy of Group A is more benefit between two groups.关键词
社区获得性肺炎/头孢哌酮/舒巴坦钠/莫西沙星/最小成本分析Key words
Community acquired pneumonia/ Cefoperazone/sulbactam sodium/ Moxifloxacin/ Cost-minimization analysis分类
医药卫生引用本文复制引用
许建国,朱华,姜正华..莫西沙星与头孢哌酮/舒巴坦钠治疗社区获得性肺炎的最小成本分析[J].中国药房,2009,20(32):2483-2485,3.
